Arcus Biosciences, Inc.

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib can slow cancer growth better than cabozantinib alone in people with advanced clear cell kidney cancer. About 720 adults whose cancer worsened after prior immunotherapy will receive…

This study looks at how the drug casdatifan is processed in the body when taken as different tablet strengths and with or without food. It involves 24 healthy adults who will receive single doses under various conditions. The goal is to check if the different forms are equivalent…